Apremilast in patients with active rheumatoid arthritis: A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Arthritis and Rheumatology

Volumn 67, Issue 7, 2015, Pages 1703-1710

  Genovese, Mark C ^a   Jarosova, Katerina ^b   Cies̈lak, Dorota ^c   Alper, Jeffrey ^d   Kivitz, Alan ^e   Hough, Douglas R ^f   Maes, Peter ^f   Pineda, Lilia ^f   Chen, Mindy ^f   Zaidi, Farrukh ^g  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d MD Research   (United States)

^e Altoona Center for Clinical Research   (United States)

^f CELGENE CORPORATION   (United States)

^g Suncoast Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; METHOTREXATE; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT; THALIDOMIDE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; DOSE RESPONSE; JOINT; LONGITUDINAL STUDY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JOINTS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84933074160     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39120     Document Type: Article

References (15)

1. Schafer P., Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012; 83: 1583-90.
2. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al., Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014; 73: 1020-6.
3. Otezla [package insert]. Summit (NJ): Celgene; 2014.
4. Otezla [summary of product characteristics]. Uxbridge (UK): Celgene Europe Ltd; 2015.
5. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
6. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al., American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
7. Fries JF, Spitz P, Kraines RG, Holman HR., Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
8. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al., Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
9. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
10. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
11. Van der Heijde DM. How to read radiographs according to the Sharp/van der Heijde method [corrected and republished in J Rheumatol 2000;27:261-3]. J Rheumatol 1999; 26: 743-5.
12. Ostergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, et al., OMERACT rheumatoid arthritis magnetic resonance imaging studies: core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system [published erratum appears in J Rheumatol 2004;31:198]. J Rheumatol 2003; 30: 1385-6.
13. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA., Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 557-60.
14. Papp K, Cather J, Rosoph L, Sofen H, Langley RG, Matheson RT, et al., The efficacy of apremilast, a phosphodiesterase-4 inhibitor, in the treatment of moderate to severe psoriasis: results of a phase 2 randomised study. Lancet 2012; 380: 738-46.
15. Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, et al., Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012; 64: 3156-67.